Thymosin Alpha-1 (Ta1)
Bestseller

Thymosin Alpha-1 (Ta1)

FDA-designated immunomodulator (Zadaxin) approved in 35+ countries for hepatitis B, hepatitis C, and cancer immunotherapy. Activates T-cells and dendritic

Immune
● In Stock

Buy more, save more

1+ vials
−5%
3+ vials
−10%
5+ vials
−20%
10+ vials

Total Price

$55

For research & laboratory use only. Not for human consumption.

Half-Life

~2 hours

Administration Route

Subcutaneous injection

Thymic Immunomodulator

Enhances T-cell maturation and NK cell cytotoxicity

Anti-viral Potency

Active against HBV, HCV, and studied in COVID-19 contexts

TLR9 Activation

Toll-like receptor 9 agonism drives innate immune priming

Effect Profile

Immune Activation

0%

Anti-Viral Defence

0%

Inflammation Control

0%

Immune Ageing

0%

Effect Timeline

Start — Week 2

T-cell activity increases; NK cell cytotoxicity elevated

Week 4

Immune surveillance improved; viral load reduction in models

Week 8

Sustained immune enhancement; TLR signalling upregulated

Week 12

Full immunomodulatory benefit; immune ageing markers reduced

Mechanism of Action

Thymosin Alpha-1 (Ta1) is a 28-amino acid acetylated peptide originally isolated from thymosin fraction 5 of thymus tissue. It is the most clinically validated thymic peptide. Ta1 activates innate immunity by binding TLR2 and TLR9 on dendritic cells and macrophages, driving MyD88-NF-kB signalling to produce IL-12 and type I interferons. It also directly promotes T-cell maturation, differentiation of Th1 effectors, and natural killer cell cytotoxicity.

Scientific Research

Product FAQs

Stacks Well With

Related Products

Cart

Your cart is empty